Sildenafil (Viagra) Corrects DeltaF508-CFTR Location in Nasal Epithelial Cells from Patients with Cystic Fibrosis

Overview

Journal Thorax

Date 2004 Dec 25

PMID 15618584

Citations 32

Authors

R L Dormer

C M Harris

Z Clark

M M C Pereira

I J M Doull

C Norez

F Becq

M A McPherson

Affiliations

Soon will be listed here.

Abstract

Background: Most patients with cystic fibrosis (CF) have a DeltaF508 mutation resulting in abnormal retention of mutant gene protein (DeltaF508-CFTR) within the cell. This study was undertaken to investigate DeltaF508-CFTR trafficking in native cells from patients with CF with the aim of discovering pharmacological agents that can move DeltaF508-CFTR to its correct location in the apical cell membrane.

Method: Nasal epithelial cells were obtained by brushing from individuals with CF. CFTR location was determined using immunofluorescence and confocal imaging in untreated cells and cells treated with sildenafil. The effect of sildenafil treatment on CFTR chloride transport function was measured in CF15 cells using an iodide efflux assay.

Results: In most untreated CF cells DeltaF508-CFTR was mislocalised within the cell at a site close to the nucleus. Exposure of cells to sildenafil (2 hours at 37 degrees C) resulted in recruitment of DeltaF508-CFTR to the apical membrane and the appearance of chloride transport activity. Sildenafil also increased DeltaF508-CFTR trafficking in cells from individuals with CF with a single copy DeltaF508 (DeltaF508/4016ins) or with a newly described CF trafficking mutation (R1283M).

Conclusions: The findings provide proof of principle for sildenafil as a DeltaF508-CFTR trafficking drug and give encouragement for future testing of sildenafil and related PDE5 inhibitors in patients with CF.

Citing Articles

Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies.

Anwar S, Peng J, Zahid K, Zhou Y, Ali Q, Qiu C Adv Respir Med. 2024; 92(4):263-277.

PMID: 39051188 PMC: 11270331. DOI: 10.3390/arm92040026.

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives.

ElHady A, El-Gamil D, Abdel-Halim M, Abadi A Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765073 PMC: 10536424. DOI: 10.3390/ph16091266.

Rhinorrhea and increased chloride secretion through the CFTR chloride channel-a systematic review.

Eisenhut M Eur Arch Otorhinolaryngol. 2023; 280(10):4309-4318.

PMID: 37338585 DOI: 10.1007/s00405-023-08067-w.

One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.

Ensinck M, Carlon M Cells. 2022; 11(12).

PMID: 35740997 PMC: 9220995. DOI: 10.3390/cells11121868.

Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie's Disease.

Miyata Y, Matsuo T, Nakamura Y, Mitsunari K, Ohba K, Sakai H Biomedicines. 2021; 9(11).

PMID: 34829887 PMC: 8615952. DOI: 10.3390/biomedicines9111658.

References

Cheadle J, Meredith A, Al-Jader L . A new missense mutation (R1283M) in exon 20 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mol Genet. 1992; 1(2):123-5. DOI: 10.1093/hmg/1.2.123. View

Kartner N, Augustinas O, Jensen T, Naismith A, Riordan J . Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet. 1992; 1(5):321-7. DOI: 10.1038/ng0892-321. View

Zeitlin P . Novel pharmacologic therapies for cystic fibrosis. J Clin Invest. 1999; 103(4):447-52. PMC: 408112. DOI: 10.1172/JCI6346. View

Kunzelmann K, Schreiber R . CFTR, a regulator of channels. J Membr Biol. 1999; 168(1):1-8. DOI: 10.1007/s002329900492. View

Kalin N, Claass A, Sommer M, Puchelle E, Tummler B . DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J Clin Invest. 1999; 103(10):1379-89. PMC: 408454. DOI: 10.1172/JCI5731. View

Becq F, Mettey Y, Gray M, Galietta L, Dormer R, Merten M . Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J Biol Chem. 1999; 274(39):27415-25. DOI: 10.1074/jbc.274.39.27415. View

Puchelle E, Gaillard D, Ploton D, Hinnrasky J, Fuchey C, Boutterin M . Differential localization of the cystic fibrosis transmembrane conductance regulator in normal and cystic fibrosis airway epithelium. Am J Respir Cell Mol Biol. 1992; 7(5):485-91. DOI: 10.1165/ajrcmb/7.5.485. View

Penque D, Mendes F, Beck S, Farinha C, Pacheco P, Nogueira P . Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab Invest. 2000; 80(6):857-68. DOI: 10.1038/labinvest.3780090. View

Dormer R, Derand R, McNeilly C, Mettey Y, Bulteau-Pignoux L, Metaye T . Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J Cell Sci. 2001; 114(Pt 22):4073-81. DOI: 10.1242/jcs.114.22.4073. View

10.

McPherson M, Pereira M, Russell D, McNeilly C, Morris R, Stratford F . The CFTR-mediated protein secretion defect: pharmacological correction. Pflugers Arch. 2002; 443 Suppl 1:S121-6. DOI: 10.1007/s004240100658. View

11.

Stratford F, Pereira M, Becq F, McPherson M, Dormer R . Benzo(c)quinolizinium drugs inhibit degradation of Delta F508-CFTR cytoplasmic domain. Biochem Biophys Res Commun. 2002; 300(2):524-30. DOI: 10.1016/s0006-291x(02)02883-8. View

12.

Gregory R, Rich D, Cheng S, Souza D, Paul S, Manavalan P . Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2. Mol Cell Biol. 1991; 11(8):3886-93. PMC: 361177. DOI: 10.1128/mcb.11.8.3886-3893.1991. View

13.

Denning G, Ostedgaard L, Welsh M . Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol. 1992; 118(3):551-9. PMC: 2289545. DOI: 10.1083/jcb.118.3.551. View

14.

McPherson M, Pereira M, Lloyd Mills C, Murray K, Dormer R . A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein. FEBS Lett. 1999; 464(1-2):48-52. DOI: 10.1016/s0014-5793(99)01672-5. View